Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Down 98.4% in April

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 3,506 shares, a decline of 98.4% from the March 31st total of 220,491 shares. Based on an average trading volume of 460,206 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Bioxytran Trading Down 3.0%

Shares of OTCMKTS BIXT opened at $0.04 on Friday. Bioxytran has a 1-year low of $0.03 and a 1-year high of $0.17. The company has a market cap of $3.97 million, a PE ratio of -1.75 and a beta of 2.50. The company has a 50-day moving average of $0.04 and a two-hundred day moving average of $0.06.

About Bioxytran

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.